Royal Biologics received FDA approval for its MAXX-BMC bone marrow aspirate concentration system.
The system is the latest addition to the company's portfolio of advanced cellular technologies and enhanced autologous healing solutions, according to a June 1 news release. Its lead screw technology is designed to create a customized sample point of care for use during orthopedic and sports medicine surgical procedures.
Royal Biologics' regenerative medicine portfolio includes platelet-rich plasma and bone marrow products.